Xing P, Michael M, Apostolopoulos V, Prenzoska J, Marshall C, Bishop J, McKenzie I
AUSTIN RES INST,HEIDELBERG,VIC 3084,AUSTRALIA. PETER MACCALLUM HOSP,MELBOURNE,VIC 3002,AUSTRALIA.
Int J Oncol. 1995 Jun;6(6):1283-9. doi: 10.3892/ijo.6.6.1283.
Exposed peptides in the repeat (VNTR) protein core of human mucin 1 (MUC1) could be a target for immunotherapy, as it is highly immunogenic in mice and a human cytotoxic T lymphocytes to MUC1 recognise the peptide. On this basis 13 patients were immunised with a MUC1 peptide - a 20 amino acids dimer conjugated with diphtheria toroid as carrier. In patients with established breast cancer increasing doses (0.15 mg, 0.25 mg, 0.5 mg, 1.0 mg) were used at 2 week intervals (3 injections). No toxicity was found, other than for DTH reaction to the diphtheria carrier; weak antibody and T cell proliferative responses were seen and weak DTH reaction in proportion of patients. The MUC1 peptide appears to be safe but in the form used was not highly immunogenic.
人黏蛋白1（MUC1）重复（VNTR）蛋白核心中暴露的肽段可能成为免疫治疗的靶点，因为它在小鼠中具有高度免疫原性，且人针对MUC1的细胞毒性T淋巴细胞能识别该肽段。基于此，13例患者用一种MUC1肽段进行免疫——一种与白喉类毒素结合作为载体的20个氨基酸的二聚体。对于确诊的乳腺癌患者，每隔2周使用递增剂量（0.15毫克、0.25毫克、0.5毫克、1.0毫克）（共注射3次）。除了对白喉载体的迟发型超敏反应外，未发现其他毒性；观察到有微弱的抗体和T细胞增殖反应，部分患者有微弱的迟发型超敏反应。MUC1肽段似乎是安全的，但所用形式的免疫原性不高。
